Sodium phosphate - Zeria

Drug Profile

Sodium phosphate - Zeria

Alternative Names: Monobasic sodium phosphate monohydrate/dibasic sodium phosphate anhydrous; Phosribbon Combination Granules; Z-521

Latest Information Update: 16 Apr 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zeria
  • Class Laxatives; Phosphates
  • Mechanism of Action Phosphate-replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - X-linked dominant hypophosphataemic rickets; Osteomalacia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypophosphataemia
  • No development reported Osteomalacia; X-linked dominant hypophosphataemic rickets

Most Recent Events

  • 16 Apr 2015 No recent reports on development identified - Preregistration for Osteomalacia (In children) and X-linked dominant hypophosphataemic rickets (In children) in Japan (PO)
  • 25 Dec 2012 Registered for Hypophosphataemia in Japan (PO)
  • 15 May 2012 Preregistration for Osteomalacia (in children) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top